Stockscreener 앱 받기
2.61
0.77%
0.02
시간 외 거래:
2.66
0.05
+1.92%
전일 마감가:
$2.59
열려 있는:
$2.61
하루 거래량:
261.84K
Relative Volume:
1.46
시가총액:
$53.64M
수익:
-
순이익/손실:
$-69.17M
주가수익비율:
-0.4394
EPS:
-5.94
순현금흐름:
$-33.93M
1주 성능:
+11.54%
1개월 성능:
+45.81%
6개월 성능:
-10.31%
1년 성능:
+93.33%
1일 변동 폭
$2.56
$2.74
1주일 범위
$2.245
$2.74
52주 변동 폭
$1.04
$5.24
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia
FDA fast tracks Protara's choline chloride therapy - Investing.com
Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire
Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance
Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com
Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily
Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India
Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada
Protara reveals high choline deficiency in PS patients - Investing.com India
Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire
Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada
Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan
Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily
Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News
Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex
A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News
Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily
Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart
Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily
Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga
TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com
TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com
TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com
Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World
Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World
Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World
HC Wainwright Reaffirms Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? - Simply Wall St
Protara Therapeutics price target lowered to $20 from $22 at Guggenheim - TipRanks
Protara Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Head to Head Review: Protara Therapeutics (NASDAQ:TARA) and Gilead Sciences (NASDAQ:GILD) - Defense World
TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - MSN
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire
Head to Head Survey: Protara Therapeutics (NASDAQ:TARA) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World
Oppenheimer & Co. Inc. Takes $40,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - American Banking and Market News
Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 11,396 Shares of Stock - Defense World
Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com India
Protara Therapeutics Inc (TARA) Becoming More Attractive for Investors - Knox Daily
Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 8,497 Shares of Stock - Defense World
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):